Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA 2 phase 3 trial of topical delgocitinib for moderate to severe chronic hand eczema
NL-OMON54950Phase 3Recruiting
- Sponsor
- LEO Pharma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Delgocitinib cream with Vehicle cream (2 arms). Primary endpoint: IGA-CHE treatment success at Week 16. Started Sep 2021; status: recruiting.
02
Drugs
delgocitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on NL-OMON54950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54950.